Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RARE Ultragenyx Pharmaceutical Inc
- Stocks
- Healthcare
- NASDAQ: RARE
Price (delayed)
$35.61
Market cap
$3.37B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.87
Enterprise value
$4.13B
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of
Highlights
The revenue rose by 33% year-on-year and by 5% since the previous quarter
The company's gross profit rose by 28% YoY and by 4% QoQ
The equity has declined by 45% since the previous quarter and by 2.2% year-on-year
The quick ratio has decreased by 4.7% QoQ and by 2.9% YoY
Key stats
What are the main financial stats of RARE
Market
Valuations
Earnings
Shares outstanding
94.54M
Market cap
$3.37B
Enterprise value
$4.13B
Price to earnings (P/E)
N/A
Price to book (P/B)
24
Price to sales (P/S)
5.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.99
Revenue
$590.69M
Gross profit
$502.83M
Operating income
-$519.36M
Net income
-$549.58M
EBIT
-$547.13M
EBITDA
-$511.44M
Free cash flow
-$395.54M
Per share
Balance sheet
Liquidity
EPS
-$5.87
EPS diluted
-$5.87
Free cash flow per share
-$4.11
Book value per share
$1.48
Revenue per share
$6.13
TBVPS
$11.33
Total assets
$1.31B
Total liabilities
$1.16B
Debt
$889.7M
Equity
$137.25M
Working capital
$407.49M
Debt to equity
6.48
Current ratio
2.4
Quick ratio
2.03
Net debt/EBITDA
-1.49
Margins
Efficiency
Dividend
EBITDA margin
-86.6%
Gross margin
85.1%
Net margin
-93%
Operating margin
-87.9%
Return on assets
-36.8%
Return on equity
-189.9%
Return on invested capital
-33.1%
Return on capital employed
-53.6%
Return on sales
-92.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RARE stock price
How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
2.21%
1 week
1.42%
1 month
1.8%
1 year
-16.43%
YTD
-15.36%
QTD
-1.66%
Financial performance
How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$590.69M
Gross profit
$502.83M
Operating income
-$519.36M
Net income
-$549.58M
Gross margin
85.1%
Net margin
-93%
The company's operating margin rose by 33% YoY and by 9% QoQ
Ultragenyx Pharmaceutical's net margin has increased by 33% YoY and by 8% from the previous quarter
The revenue rose by 33% year-on-year and by 5% since the previous quarter
The company's gross profit rose by 28% YoY and by 4% QoQ
Price vs fundamentals
How does RARE's price correlate with its fundamentals
Growth
What is Ultragenyx Pharmaceutical's growth rate over time
Valuation
What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
24
P/S
5.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.99
RARE's EPS is up by 26% year-on-year and by 7% since the previous quarter
RARE's price to book (P/B) is 60% more than its 5-year quarterly average of 15.0 and 52% more than its last 4 quarters average of 15.8
The equity has declined by 45% since the previous quarter and by 2.2% year-on-year
The P/S is 57% lower than the 5-year quarterly average of 13.6 and 24% lower than the last 4 quarters average of 7.6
The revenue rose by 33% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is Ultragenyx Pharmaceutical business performance
The ROE has soared by 55% year-on-year and by 3.2% since the previous quarter
RARE's return on sales is up by 33% year-on-year and by 9% since the previous quarter
The return on assets has increased by 20% year-on-year and by 3.7% since the previous quarter
The company's return on invested capital rose by 9% YoY
Dividends
What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RARE.
Financial health
How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 13% more than the total liabilities
The total assets has contracted by 13% from the previous quarter
The company's total liabilities fell by 6% QoQ
Ultragenyx Pharmaceutical's debt to equity has soared by 77% from the previous quarter but it has decreased by 2.6% YoY
The equity has declined by 45% since the previous quarter and by 2.2% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.